A Study on Whether Patients Prefer the Spiriva® Respimat® or the Spiriva® Handihaler® for Treating Their Chronic Obstructive Pulmonary Disease (COPD)

NCT03964207 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: Tiotropium Respimat® (T1)
DRUG: Tiotropium Handihaler® (T2)

Sponsor

Boehringer Ingelheim